TAK 285

Drug Profile

TAK 285

Alternative Names: TAK-285

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 03 Feb 2011 Discontinued - Phase-I for Cancer in USA (PO)
  • 03 Feb 2011 Discontinued - Phase-I for Solid tumours in Japan (PO)
  • 14 Dec 2008 Pharmacodynamics data from a preclinical study in breast cancer presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top